RESUMO
Aim: Nanomaterials and nanomedicinal products tend to interfere with various commonly used assays, including regulatory required endotoxin detection methods for medicines. We developed a method to quantify endotoxin levels that is compatible with nanomaterials and nanomedicinal products. Materials & methods: The method is based on measuring endotoxin indirectly via 3-hydroxylated fatty acids of lipid-A, using Ultra High Performance Liquid Chromatography coupled with mass spectrometry. The outcome was related to results of the commonly used Limulus Amebocyte Lysate method. Results: The ultra high performance liquid chromatography coupled with mass spectrometry method has clear advantages compared with other endotoxin determination assays; particularly the absence of nanospecific interference. Conclusion: The method is sensitive, straightforward and accurate in determining and quantifying endotoxin in nanomedicinal product samples.
Assuntos
Lipopolissacarídeos/análise , Nanoestruturas/química , Bioensaio , Cério/química , Cromatografia Líquida de Alta Pressão , Dendrímeros/química , Ácidos Graxos/análise , Compostos Férricos/química , Lipossomos/química , Proteínas de Membrana/química , Nanomedicina , Tamanho da Partícula , Espectrometria de Massas em Tandem , Titânio/químicaRESUMO
Within the EU FP-7 GUIDEnano project, a methodology was developed to systematically quantify the similarity between a nanomaterial (NM) that has been tested in toxicity studies and the NM for which risk needs to be evaluated, for the purpose of extrapolating toxicity data between the two materials. The methodology is a first attempt to use current knowledge on NM property-hazard relationships to develop a series of pragmatic and systematic rules for assessing NM similarity. Moreover, the methodology takes into account the practical feasibility, in that it is based on generally available NM characterization information. In addition to presenting this methodology, the lessons learnt and the challenges faced during its development are reported here. We conclude that there is a large gap between the information that is ideally needed and its application to real cases. The current database on property-hazard relationships is still very limited, which hinders the agreement on the key NM properties constituting the basis of the similarity assessment and the development of associated science-based and unequivocal rules. Currently, one of the most challenging NM properties to systematically assess in terms of similarity between two NMs is surface coating and functionalization, which lacks standardized parameters for description and characterization methodology. Standardization of characterization methods that lead to quantitative, unambiguous, and measurable parameters describing NM properties are necessary in order to build a sufficiently robust property-hazard database that allows for evidence-based refinement of our methodology, or any other attempt to systematically assess the similarity of NMs.
Assuntos
Segurança Química/métodos , Bases de Dados Factuais , Substâncias Perigosas/classificação , Nanoestruturas/classificação , Substâncias Perigosas/química , Substâncias Perigosas/toxicidade , Humanos , Nanoestruturas/química , Nanoestruturas/toxicidade , Relação Estrutura-AtividadeRESUMO
Due to their specific properties and pharmacokinetics, nanomedicinal products (NMPs) may present different toxicity and side effects compared to non-nanoformulated, conventional medicines. To facilitate the safety assessment of NMPs, we aimed to gain insight into toxic effects specific for NMPs by systematically analyzing the available toxicity data on approved NMPs in the European Union. In addition, by comparing five sets of products with the same active pharmaceutical ingredient (API) in a conventional formulation versus a nanoformulation, we aimed to identify any side effects specific for the nano aspect of NMPs. The objective was to investigate whether specific toxicity could be related to certain structural types of NMPs and whether a nanoformulation of an API altered the nature of side effects of the product in humans compared to a conventional formulation. The survey of toxicity data did not reveal nanospecific toxicity that could be related to certain types of structures of NMPs, other than those reported previously in relation to accumulation of iron nanoparticles (NPs). However, given the limited data for some of the product groups or toxicological end points in the analysis, conclusions with regard to (a lack of) potential nanomedicine-specific effects need to be considered carefully. Results from the comparison of side effects of five sets of drugs (mainly liposomes and/or cytostatics) confirmed the induction of pseudo-allergic responses associated with specific NMPs in the literature, in addition to the side effects common to both nanoformulations and regular formulations, eg, with liposomal doxorubicin, and possibly liposomal daunorubicin. Based on the available data, immunotoxicological effects of certain NMPs cannot be excluded, and we conclude that this end point requires further attention.
Assuntos
Nanoestruturas/efeitos adversos , Nanoestruturas/toxicidade , Albuminas/efeitos adversos , Anfotericina B/administração & dosagem , Anfotericina B/efeitos adversos , Daunorrubicina/administração & dosagem , Daunorrubicina/efeitos adversos , Doxorrubicina/análogos & derivados , Doxorrubicina/toxicidade , Portadores de Fármacos/efeitos adversos , Humanos , Lipossomos/efeitos adversos , Lipossomos/química , Nanomedicina/métodos , Nanopartículas/toxicidade , Nanoestruturas/química , Paclitaxel/efeitos adversos , Polietilenoglicóis/toxicidade , Inquéritos e QuestionáriosRESUMO
Nanomaterials (NMs) are attractive for biomedical and pharmaceutical applications because of their unique physicochemical and biological properties. A major application area of NMs is drug delivery. Many nanomedicinal products (NMPs) currently on the market or in clinical trials are most often based on liposomal products or polymer conjugates. NMPs can be designed to target specific tissues, eg, tumors. In virtually all cases, NMPs will eventually reach the immune system. It has been shown that most NMs end up in organs of the mononuclear phagocytic system, notably liver and spleen. Adverse immune effects, including allergy, hypersensitivity, and immunosuppression, have been reported after NMP administration. Interactions of NMPs with the immune system may therefore constitute important side effects. Currently, no regulatory documents are specifically dedicated to evaluate the immunotoxicity of NMs or NMPs. Their immunotoxicity assessment is performed based on existing guidelines for conventional substances or medicinal products. Due to the unique properties of NMPs when compared with conventional medicinal products, it is uncertain whether the currently prescribed set of tests provides sufficient information for an adequate evaluation of potential immunotoxicity of NMPs. The aim of this study was therefore, to compare the current regulatory immunotoxicity testing requirements with the accumulating knowledge on immunotoxic effects of NMPs in order to identify potential gaps in the safety assessment. This comparison showed that immunotoxic effects, such as complement activation-related pseudoallergy, myelosuppression, inflammasome activation, and hypersensitivity, are not readily detected by using current testing guidelines. Immunotoxicity of NMPs would be more accurately evaluated by an expanded testing strategy that is equipped to stratify applicable testing for the various types of NMPs.
Assuntos
Sistema Imunitário/efeitos dos fármacos , Nanomedicina/métodos , Nanoestruturas/toxicidade , Testes de Toxicidade/normas , Animais , Sistemas de Liberação de Medicamentos/efeitos adversos , Sistemas de Liberação de Medicamentos/métodos , Guias como Assunto , Humanos , Tolerância Imunológica/efeitos dos fármacos , Nanomedicina/legislação & jurisprudência , Nanoestruturas/efeitos adversos , Baço/efeitos dos fármacos , Testes de Toxicidade/métodosRESUMO
Nanotechnology applications already on the market or in development promise great benefits for humans as well as the environment. Simultaneously, the pressure to advance the development of fast methods for evaluating the potential risks of increased human exposure to nanomaterials is augmented. One way forward would be to enhance the role of in vitro toxicity studies in risk assessment procedures of nanomaterials. However, to maximize the use of in vitro assays for this purpose, their values and limitations need to be revealed. Even in risk assessment frameworks for regular chemicals, in vitro studies play a minor role. A comparative analysis of published in vitro data with nanomaterials demonstrates that there are a number of issues that need resolving before in vitro studies can play a role in the risk assessment of nanomaterials.